Research Study

Phase II/III Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of 2 Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease
Principal Investigator 
Ging-Yuek Robin Hsiung

Overview

Body Locations and Systems 
Disorders and Conditions 
ClinicalTrials.gov# 
NCT01760005
Status 
Closed to Recruitment
Study Start/End 
Apr 22, 2014 to Jun 1, 2016
Locations 
UBC Hospital
Name/Title 
Michele Assaly, Research Coordinator
Phone 
604-822-1782
Email Address 
michele.assaly@vch.ca
Purpose of Study 

The purpose of this study is to assess the safety, tolerability, biomarker and cognitive efficacy of gantenerumab and solanezumab in subjects who are known to have an Alzheimer's disease-causing mutation by determining if treatment with the study drug improves cognitive outcomes and disease-related biomarkers.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.